Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
May 26 AMGN Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
May 26 AMGN The Biggest Publicly Traded Biotech Company
May 25 AMGN Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
May 25 AMGN It's Unlikely That Amgen Inc.'s (NASDAQ:AMGN) CEO Will See A Huge Pay Rise This Year
May 24 SNY Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
May 24 LNTH Here's Why Lantheus Holdings (LNTH) is a Strong Growth Stock
May 24 AMGN The Zacks Analyst Blog Highlights Apple, Mastercard, Amgen, Utah Medical Products and Bridger Aerospace
May 23 MYGN Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23 AMGN Top Stock Reports for Apple, Mastercard & Amgen
May 23 LNTH Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
May 23 AYTU Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 23 SNY Sanofi reports positive data from Phase II asthma treatment trial
May 22 SNY Sanofi says asthma candidate rilzabrutinib buoyed by phase 2 results
May 22 SNY Bristol-Myers, Sanofi liability in Hawaii Plavix litigation tops $900M
May 22 SNY Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
May 22 SNY First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
May 22 SNY Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
May 22 VERU Individual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%
May 22 SNY Better Buy: Inovio Pharmaceuticals vs. Novavax
May 22 INO Better Buy: Inovio Pharmaceuticals vs. Novavax
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags